Correction
Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
1 Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
2 Endocrine Division, Universidade Federal do Rio Grande do Sul, Avenida Paulo Gama 110-Reitoria, Porto Alegre 90040-060, Brazil
3 Global Biometric Services, Bristol-Myers Squibb, Parc de l’Alliance, Avenue de Finlande 4, Braine I’Alleud B-1420, Belgium
4 Global Clinical Research, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA
BMC Medicine 2013, 11:193 doi:10.1186/1741-7015-11-193
Published: 2 September 2013First paragraph (this article has no abstract)
The authors note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.
